Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE-HTx: Everolimus vs MMF in Heart Transplant
NCT06942156Phase 4Not yet recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in heart transplantation (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Hierarchical composite assessed using the win-ratio at 12 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
heart transplantation
Beyond the preview
Go deeper on NCT06942156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942156.